{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:27:21Z","timestamp":1781087241332,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,28]]},"DOI":"10.7759\/cureus.91170","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:28:01Z","timestamp":1756380481000},"source":"Crossref","is-referenced-by-count":2,"title":["Central Retinal Artery Occlusion After Intravitreal Injection of Faricimab: A Case Report"],"prefix":"10.7759","author":[{"given":"Hiromasa","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1521358","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database","volume":"16","author":"He CZ","year":"2025","unstructured":"He CZ, Qiu Q, Lu SJ, Xue FL, Liu JQ, He Y. Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2025, 16:1521358. 10.3389\/fphar.2025.1521358","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-024-00416-y","article-title":"Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature","volume":"11","author":"Lee YM","year":"2024","unstructured":"Lee YM, Gurung R, Gilhotra JS, Simon S, Cugati S. Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature. Eye Vis (Lond). 2024, 11:48. 10.1186\/s40662-024-00416-y","journal-title":"Eye Vis (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0928","article-title":"Association of occlusive retinal vasculitis with intravitreal faricimab","volume":"142","author":"Li Y","year":"2024","unstructured":"Li Y, Chong R, Fung AT. Association of occlusive retinal vasculitis with intravitreal faricimab. JAMA Ophthalmol. 2024, 142:489-91. 10.1001\/jamaophthalmol.2024.0928","journal-title":"JAMA Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83764","article-title":"Intraocular inflammation following faricimab intravitreal injection treated with sub-tenon triamcinolone acetonide injection","volume":"17","author":"Yasuda S","year":"2025","unstructured":"Yasuda S, Tsujinaka H, Nishiyama T, Mizusawa Y, Ueda T. Intraocular inflammation following faricimab intravitreal injection treated with sub-tenon triamcinolone acetonide injection. Cureus. 2025, 17:e83764. 10.7759\/cureus.83764","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-024-00429-7","article-title":"Occlusive retinal vasculitis associated with intravitreal Faricimab injections","volume":"14","author":"Reichel FF","year":"2024","unstructured":"Reichel FF, Kiraly P, Vemala R, Hornby S, De Silva SR, Fischer MD. Occlusive retinal vasculitis associated with intravitreal Faricimab injections. J Ophthalmic Inflamm Infect. 2024, 14:45. 10.1186\/s12348-024-00429-7","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v19i4.16559","article-title":"Retinal artery occlusion: a review of current management practices","volume":"19","author":"Yu HJ","year":"2024","unstructured":"Yu HJ, Choi S, Guiseppi R, Banaee T. Retinal artery occlusion: a review of current management practices. J Ophthalmic Vis Res. 2024, 19:488-507. 10.18502\/jovr.v19i4.16559","journal-title":"J Ophthalmic Vis Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.017","article-title":"Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration","volume":"116","author":"Papadopoulou DN","year":"2009","unstructured":"Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology. 2009, 116:1755-61. 10.1016\/j.ophtha.2009.03.017","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14058","article-title":"Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections","volume":"97","author":"Gao X","year":"2019","unstructured":"Gao X, Borkar D, Obeid A, Hsu J, Ho AC, Garg SJ. Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections. Acta Ophthalmol. 2019, 97:e938-9. 10.1111\/aos.14058","journal-title":"Acta Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211066196","article-title":"Transient central retina artery occlusion in patients undergoing intravitreal anti vegf injections","volume":"32","author":"Damasceno NA","year":"2022","unstructured":"Damasceno NA, Yannuzzi NA, Maia M, Eid Farah M, Flynn HW Jr, Damasceno EF. Transient central retina artery occlusion in patients undergoing intravitreal anti vegf injections. Eur J Ophthalmol. 2022, 32:2819-23. 10.1177\/11206721211066196","journal-title":"Eur J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01406.x","article-title":"Retinal artery occlusion following intravitreal anti-VEGF therapy","volume":"88","author":"von Hanno T","year":"2010","unstructured":"von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol. 2010, 88:263-6. 10.1111\/j.1755-3768.2008.01406.x","journal-title":"Acta Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91832-w","article-title":"Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration","volume":"11","author":"Maruyama-Inoue M","year":"2021","unstructured":"Maruyama-Inoue M, Inoue T, Mohamed S, Kitajima Y, Ikeda S, Ito A, Kadonosono K. Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration. Sci Rep. 2021, 11:12246. 10.1038\/s41598-021-91832-w","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01535.x","article-title":"Retinal vascular events after intravitreal bevacizumab","volume":"88","author":"Mansour AM","year":"2010","unstructured":"Mansour AM, Bynoe LA, Welch JC, Pesavento R, Mahendradas P, Ziemssen F, Pai SA. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol. 2010, 88:730-5. 10.1111\/j.1755-3768.2009.01535.x","journal-title":"Acta Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug SJ","year":"2020","unstructured":"Haug SJ, Hien DL, Uludag G, et al.. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020, 18:100680. 10.1016\/j.ajoc.2020.100680","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s J","year":"2021","unstructured":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, et al.. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021, 128:1050-9. 10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03452-3","article-title":"Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-na\u00efve neovascular age-related macular degeneration; a case report","volume":"24","author":"Hong SH","year":"2024","unstructured":"Hong SH, Kim HD. Central retinal artery occlusion after intravitreal brolucizumab injection for treatment-na\u00efve neovascular age-related macular degeneration; a case report. BMC Ophthalmol. 2024, 24:200. 10.1186\/s12886-024-03452-3","journal-title":"BMC Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101521","article-title":"Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation","volume":"26","author":"Kusuhara S","year":"2022","unstructured":"Kusuhara S, Kim KW, Miki A, Nakamura M. Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation. Am J Ophthalmol Case Rep. 2022, 26:101521. 10.1016\/j.ajoc.2022.101521","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha FM","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et al.. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024, 10:5. 10.1186\/s40942-024-00525-9","journal-title":"Int J Retina Vitreous"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404580-central-retinal-artery-occlusion-after-intravitreal-injection-of-faricimab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:28:01Z","timestamp":1756380481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404580-central-retinal-artery-occlusion-after-intravitreal-injection-of-faricimab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.91170","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}